收藏切换
Research Progress of Drugs for Human Cytomegalovirus
收藏切换
Mengfei DONG1, Tailin WANG2, Jingyi ZHANG1, Wenxia ZOU1, Shu HAN1, Xianglei LIU1, *
Chinese Journal of Pharmaceuticals | 2026, 57(9) : 1023 - 1029
Less
收藏切换
Chinese Journal of Pharmaceuticals | 2026, 57(9): 1023-1029
• Perspective & Review •
Research Progress of Drugs for Human Cytomegalovirus
Full
Mengfei DONG1, Tailin WANG2, Jingyi ZHANG1, Wenxia ZOU1, Shu HAN1, Xianglei LIU1, *
Affiliations
  • 1National Key Lab. of Lead Druggability Research, Shanghai Institute of Pharmaceutical Industry Co., Ltd., China State Institute of Pharmaceutical Industry, Shanghai 201203
  • 2Changsha Health Vocational College, Changsha 410600
Published: 2026-09-10 doi: 10.16522/j.cnki.cjph.2026.09.001
Outline
收藏切换

Human cytomegalovirus(HCMV) has an infection rate of over 90% in the general population. Although it mostly remains in an asymptomatic latent-infection state, it is the major pathogen responsible for congenital infection in newborns and fatal complications in immunocompromised patients. Currently, the prevention and treatment of HCMV infection face multiple challenges, including drug resistance, toxicity, and immune escape, highlighting the urgent need to integrate novel drugs and therapeutic strategies. The HCMV prevention and treatment strategies are evolving from single antiviral approaches toward multimodal synergistic directions. In the future, it will be necessary to combine structural biology, immune engineering, and clinical translational research to optimize comprehensive intervention systems. This review summarizes the research progress and future prospects of different types of drugs or strategies, including HCMV vaccines, anti-HCMV drugs, HCMV antibody drugs, and specific T-cell infusion therapy, with the aim of providing a reference for optimizing HCMV prevention and treatment strategies.

human cytomegalovirus  /  antiviral drug  /  specific T cell infusion therapy  /  vaccine  /  antibody drug  /  research progress
董梦菲, 王太林, 张婧怡, 邹文霞, 韩姝, 刘向磊. 抗人巨细胞病毒药物研究进展. 中国医药工业杂志, 2026 , 57 (9) : 1023 -1029 . DOI: 10.16522/j.cnki.cjph.2026.09.001
Mengfei DONG, Tailin WANG, Jingyi ZHANG, Wenxia ZOU, Shu HAN, Xianglei LIU. Research Progress of Drugs for Human Cytomegalovirus[J]. Chinese Journal of Pharmaceuticals, 2026 , 57 (9) : 1023 -1029 . DOI: 10.16522/j.cnki.cjph.2026.09.001
Year 2026 volume 57 Issue 9
364
94
Cite this Article
BibTeX
Article Info
doi: 10.16522/j.cnki.cjph.2026.09.001
  • Receive Date:2026-02-28
  • Online Date:2026-10-29
  • Published:2026-09-10
Article Data
Affiliations
History
  • Received:2026-02-28
Funding
Affiliations
    1National Key Lab. of Lead Druggability Research, Shanghai Institute of Pharmaceutical Industry Co., Ltd., China State Institute of Pharmaceutical Industry, Shanghai 201203
    2Changsha Health Vocational College, Changsha 410600
References
Share
https://castjournals.cast.org.cn/joweb/zgyygy/EN/10.16522/j.cnki.cjph.2026.09.001
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT